{"entity":{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","aka":["Bolt Bio","NASDAQ:BOLT"],"tldr":"Bolt Biotherapeutics builds antibodies that carry an immune-stimulating payload into tumours so the body's own myeloid cells attack the cancer; BDC-4182 aims this at Claudin 18.2.","summary":"Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates (ISACs), which link a tumour-targeting antibody to a Toll-like receptor agonist that activates myeloid cells inside the tumour. Its first programme, the HER2-directed trastuzumab imbotolimod (BDC-1001), was followed by BDC-3042, a Dectin-2 agonist antibody, and BDC-4182, a Claudin 18.2 ISAC that entered the clinic for gastric and pancreatic cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.boltbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["bdc-4182"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Redwood City, California","country":"US","companyType":"biotech","website":"https://www.boltbio.com/","ticker":"NASDAQ:BOLT","founded":2015,"stage":"public","investors":[],"funding":[]},"route":"/companies/bolt-biotherapeutics/","neighbours":{"drug":[{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/"}]}}